

The Chemours Company

Investor Presentation

August 2018



Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance, business plans and prospects, capital investments and projects, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, and our outlook for Adjusted EBITDA, Adjusted EPS and Free Cash Flow, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2017. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles ("GAAP"). Within this presentation we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, ROIC and Net Leverage Ratio to evaluate the company's performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Additional information for investors is available on the company's website at investors.chemours.com.

The Chemours Company at a Glance




(\$ in millions)

Total Chemours

Fluoroproducts

Chemical Solutions

Titanium Technologies



1. Data represents net sales for the trailing twelve months ending June 30, 2018
 See reconciliation of Non-GAAP measures in the appendix



Second Quarter 2018 Financial Summary

(\$ in millions unless otherwise noted)

	2Q18	2Q17	Δ Yr/Yr
Net Sales	\$1,816	\$1,588	\$228
Net Income ¹	281	161	120
Adj. Net Income	314	164	150
EPS ²	\$1.53	\$0.84	\$0.69
Adj. EPS ²	\$1.71	\$0.86	\$0.85
Adj. EBITDA	497	361	136
<i>Adj. EBITDA Margin (%)</i> ³	27.4	22.7	4.7
Free Cash Flow ⁴	217	115	102
Pre-Tax ROIC (%) ⁵	42	27	15

Year-Over-Year

- Broad-based revenue growth across segments drove 14% revenue increase
- Nearly doubled Adjusted EPS to \$1.71 per share from \$0.86 per share
- Adjusted EBITDA Margin expanded 470bps
- Significant Free Cash Flow improvement despite elevated capital expenditures
- Pre-tax ROIC of 42%, well above 30% threshold

¹ Net Income attributable to Chemours

² Calculation based on diluted share count

³ Defined as Adjusted EBITDA divided by Net Sales

⁴ Defined as Cash from Operations minus cash used for PP&E purchases

⁵ Defined as Adjusted EBITDA less depreciation & amortization on a trailing twelve-month basis divided by average invested capital over the last five quarters

See reconciliation of Non-GAAP measures in the Appendix



Fluoroproducts Business Summary

BUSINESS OVERVIEW

- Global market leader in Fluoroproducts
- Supplies fluoropolymer products for high performance applications across broad array of industries
- Supplies fluorochemical products for air conditioning, refrigeration and foam blowing agent markets
- Brands: Teflon™, Freon™, Opteon™, Krytox™, Nafion™, Viton™

FINANCIAL SUMMARY

\$ Millions	TTM 2Q17	TTM 2Q18	% Δ
Revenue	\$2,520	\$2,826	12%
Adjusted EBITDA	\$607	\$754	24%
Adj. EBITDA Margin	24%	27%	300bps



Fluoropolymers – industrial resins and specialty products and coatings

Fluorochemicals – refrigerants, propellants, foam blowing agents, fire suppressants

Key end markets – air conditioning, refrigeration, automotive, electronics, communications, wire & cable, energy, consumer, oil & gas, aerospace

Fluoropolymers Target Markets for Application Development

Automotive



2016
Market Size*

1,100

2016 - 2027
CAGR

5%

2027
Market Size*

1,900

Trends and Fluoropolymer Opportunities

- Emission standards and fuel efficiency with internal combustion engines
- Decarbonization of transportation via alternative energy
- Active safety and infotainment

Renewable Energy & Storage




105

21%

850

- Development of smart grid with increasing amount of renewable energy and energy storage
- Government and OEM driven alternative energy vehicles

Consumer Electronics & Communications



910

9%


2,300

- Growth and innovation in smart phones, wearables, IoT, artificial intelligence, etc.
- Next generation connectivity (5G), advances in circuit boards, LAN, antennas, thermal and electrical shielding




Chemours Fluoropolymers Impact

- Expect growth in both core and differentiated product lines over the next ten years
 - GDP-like CAGR for core
 - 10-15% CAGR for differentiated products
- Anticipate differentiated products to become a more meaningful piece of the Fluoropolymers portfolio over time
 - Attractive long-term mega trends




Fluorochemicals Long-Term Market View

■ Non-HFOs ■ HFOs



Chemours Is Well Positioned to Capture Market Growth and Value for Both HFOs and Non-HFOs


Opteon™ Advantage - CO₂ Equivalent Basis



Opteon™ Offers Low GWP Alternatives that Meet Tightening Environmental Standards

Chemours Anticipated Fluorochemicals Conversion to Opteon™

- Full conversion to low GWP technology in US mobile expected by 2021, driven by CAFE credits
- Stationary refrigerant conversion to low GWP technology ramping up over next decade, driven by EU F-Gas and Kigali Amendment



Chemical Solutions Business Overview


BUSINESS OVERVIEW

- Portfolio of industrial businesses primarily operating in the Americas
- Reputation for safety, reliability and stewardship
- Three production facilities located in North America
 - Memphis, TN: Mining Solutions
 - Belle, WV: PC&I
 - Pascagoula, MS: PC&I


FINANCIAL SUMMARY

\$ Millions	TTM 2Q17	TTM 2Q18	% Δ
Revenue	\$602	\$579	(4%)
Adjusted EBITDA	\$37	\$64	76%
Adj. EBITDA Margin	6%	11%	500bps

Product¹



Geography¹




Mining Solutions – sodium cyanide, hydrogen cyanide

Performance Chemicals & Intermediates – methylamines, glycolic acid, Vazo™ products, aniline, nitrobenzene



Chemours Chemical Solutions Strategic Priorities



Titanium Technologies Business Overview


BUSINESS OVERVIEW

- A global leader¹ in TiO₂ with production capacity of 1.25 million metric tons
 - 4 TiO₂ plants with 7 production lines
 - Packaging facility at Kallo, Belgium
 - Mineral sands mine at Starke, FL
- Strong brand reputation
 - Ti-Pure™ sold to approximately 700 customers globally
- Industry-leading manufacturing cost position
 - Unique chloride technology
 - Feedstock flexibility


FINANCIAL SUMMARY

\$ Millions	TTM 2Q17	TTM 2Q18	% Δ
Revenue	\$2,622	\$3,300	26%
Adjusted EBITDA	\$652	\$1,099	68%
Adj. EBITDA Margin	25%	33%	800bps

Product²



Geography²



Coatings – architectural, industrial, automotive

Plastics – rigid/flexible packaging, PVC pipe/windows

Papers – laminate papers, coated paper/paperboard, sheet


Chemours' Vision of Ti-Pure™ Value Stabilization

CHEMOURS' VISION

- We absorb the demand variance in our customer's marketplace, while maintaining value-based pricing for Ti-Pure™ products
- Reduced business volatility stabilizes Chemours' cash generation and enables more consistent capacity planning to serve our customers
- We can support and grow our investment in new offerings over time, enhancing growth options for our customers
- Our customers can focus their efforts on market growth and avoid the distracting seesaw of "Can I get the TiO₂ I need?" or "How high will the price go?"


CHEMOURS' APPROACH

- Create contractual relationships which support a more stable customer-Chemours relationship
- Improve our manufacturing flexibility and capacity to economically respond to both decreases and increases in our customers' sales which vary their requirements for Ti-Pure™ TiO₂
- Deliver value from a sustained investment in market insights and new offering development



Chemours' Enhanced Circuit Manufacturing Capacity


- Chemours is committed to regularly adding incremental capacity at high capital return
 - Technology-enabled debottlenecking will further increase our economy of scale advantage
 - Improving our world class uptime capability through strong operational discipline and structured continuous improvement
 - Developing long-term capacity plans to support customer growth
 - Supported with capital investment to expand our ilmenite mine and long-term ore contracts



Additional ~10% Flexible Capacity Will Support Our Customers' Growth

Chemours Titanium Technologies Strategic Priorities

Chemours Titanium Technologies is driving a robust business model focused on durable growth



- Stabilizing the value of Ti-Pure™ TiO₂, which is good for our customers, investors and suppliers
- Renewing our focus on customers and offerings
- Being the go-to supplier supporting customer growth through reliable supply, regular capacity addition and innovative offerings
- Improving our unique manufacturing skills for increased product and production flexibility at an advantaged cost
- Participating in China's development



2018 Outlook¹

Adjusted
EBITDA

Top End Of:
\$1.70 - \$1.85 Billion

Adjusted
EPS

\$5.00 - \$5.75

Free
Cash Flow


> \$700 Million

Key Factors and Assumptions²

- 2018 Ti-Pure™ realized average price above 2017 average price
- Continued Opteon™ adoption
- Fluoropolymers volume growth
- Includes benefit from ~\$500M in completed share repurchases



Expect to Meet or Exceed Three-Year Targets



1. Subject to quarterly Board approval



Returning Meaningful Cash to Shareholders

- Invest in organic growth
- Consider opportunistic M&A growth

- Meaningful return of cash to shareholders

- Maintain a BB/BB+ balance sheet

- Declared 3Q18 dividend of **\$0.25 per share**
 - An **\$0.08** increase per share
 - Expect **2018 annual dividend¹** to be **~\$150M**
 - Defensible through the cycle
 - Anticipate to grow with earnings
- Authorized **\$750M** share repurchase plan through 2020
 - Completed previous \$500M share repurchase plan during second quarter 2018
- Expect to return majority of generated Free Cash Flow to shareholders through 2020

Chemours Investment Thesis

Leveraging

industry-leading positions to drive top-line growth of 1x-2x GDP

Investing

in our core businesses with high ROIC (+30%) projects to drive sustainable competitive advantage

Strengthening

our existing businesses through targeted M&A

Returning

the majority of our Free Cash Flow to shareholders over time through a growing dividend and meaningful share repurchases

Harnessing

the energy of the organization, generated through the transformation, to move at high velocity



The Chemours Company

Reconciliations



Segment Net Sales and Adjusted EBITDA (Unaudited)

(\$ in millions unless otherwise noted)	Three Months Ended		Three Months Ended		Twelve Months Ended	
	June 30,		March 31,		June 30,	
	2018	2017	2018	2018	2017	
SEGMENT NET SALES						
Fluoroproducts	\$ 801	\$ 710	\$ 732	\$ 2,826	\$ 2,520	
Chemical Solutions	153	149	144	579	602	
Titanium Technologies	862	729	854	3,300	2,622	
Total Company	<u>\$ 1,816</u>	<u>\$ 1,588</u>	<u>\$ 1,730</u>	<u>\$ 6,705</u>	<u>\$ 5,744</u>	
SEGMENT ADJUSTED EBITDA						
Fluoroproducts	\$ 230	\$ 197	\$ 206	\$ 754	\$ 607	
Chemical Solutions	16	7	11	64	37	
Titanium Technologies	295	193	294	1,099	652	
Corporate & Other	(44)	(36)	(43)	(177)	(142)	
Total Company	<u>\$ 497</u>	<u>\$ 361</u>	<u>\$ 468</u>	<u>\$ 1,740</u>	<u>\$ 1,154</u>	
SEGMENT ADJUSTED EBITDA MARGIN						
Fluoroproducts	28.7%	27.7%	28.1%	26.7%	24.1%	
Chemical Solutions	10.5%	4.7%	7.6%	11.1%	6.1%	
Titanium Technologies	34.2%	26.5%	34.4%	33.3%	24.9%	
Corporate & Other	0.0%	0.0%	0.0%	0.0%	0.0%	
Total Company	<u>27.4%</u>	<u>22.7%</u>	<u>27.1%</u>	<u>26.0%</u>	<u>20.1%</u>	



GAAP Net Income to Adjusted EBITDA Reconciliations (Unaudited)

(\$ in millions except per share amounts)	Three Months Ended		Three Months	Twelve Months Ended	
	June 30,		March 31,	June 30,	
	2018	2017	2018	2018	2017
	\$ amounts	\$ amounts	\$ amounts	\$ amounts	\$ amounts
Income before income taxes	\$ 323	\$ 225	\$ 381	\$ 1,217	\$ 360
Interest expense, net	48	54	52	209	213
Depreciation and amortization	72	71	70	273	287
Non-operating pension and other post-retirement employee benefit income	(7)	(10)	(7)	(30)	(24)
Exchange gains, net	(2)	(2)	—	2	30
Restructuring and other charges	9	6	10	58	42
Asset-related and other charges	1	2	—	2	63
Loss on extinguishment of debt	38	1	—	38	-
(Gain) loss on sale of assets or businesses	(3)	2	(42)	(53)	(180)
Transaction costs	9	2	—	10	6
Legal and other charges	9	10	4	14	357
Adjusted EBITDA	\$ 497	\$ 361	\$ 468	\$ 1,740	\$ 1,154



GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS Reconciliations (Unaudited)

(\$ in millions except per share amounts)	Three Months Ended				Three Months Ended	
	June 30,				March 31,	
	2018		2017		2018	
	\$ amounts	\$ per share*	\$ amounts	\$ per share*	\$ amounts	\$ per share*
Net income attributable to Chemours	\$ 281	\$ 1.53	\$ 161	\$ 0.84	\$ 297	\$ 1.58
Non-operating pension and other post-retirement employee benefit income	(7)	(0.04)	(10)	(0.05)	(7)	(0.04)
Exchange gains, net	(2)	(0.01)	(2)	(0.01)	—	—
Restructuring and other charges	9	0.05	6	0.03	10	0.05
Asset-related and other charges	1	0.01	2	0.01	—	—
Loss on extinguishment of debt	38	0.21	1	0.01	—	—
(Gain) loss on sale of assets or businesses (1)	(3)	(0.02)	2	0.01	(42)	(0.22)
Transaction costs (2)	9	0.05	2	0.01	—	—
Legal and other charges (3)	10	0.05	10	0.05	4	0.02
Adjustments made to income taxes (4,6)	(8)	(0.04)	(3)	(0.02)	(5)	(0.03)
(Benefit from) provision for income taxes relating to reconciling items (5,6)	(14)	(0.08)	(5)	(0.03)	9	0.05
Adjusted Net Income	\$ 314	\$ 1.71	\$ 164	\$ 0.86	\$ 266	\$ 1.41
Net income attributable to non-controlling interests	1	—	—	—	—	—
Interest expense, net	48	—	54	—	52	—
All remaining depreciation and amortization	71	—	71	—	70	—
All remaining provision for income taxes (6)	63	—	72	—	80	—
Adjusted EBITDA	\$ 497	\$ —	\$ 361	\$ —	\$ 468	\$ —
Weighted-average number of common shares outstanding - basic	177,798,484	—	185,069,436	—	182,069,982	—
Weighted-average number of common shares outstanding - diluted	183,821,241	—	191,126,639	—	188,333,197	—
Basic earnings per share of common stock	\$ 1.58	\$ 0.87	\$ 1.63	\$ 1.58	\$ 1.63	\$ 1.58
Diluted earnings per share of common stock	1.53	0.84	1.46	1.58	1.58	1.58
Adjusted basic earnings per share of common stock	1.77	0.89	1.46	1.46	1.46	1.46
Adjusted diluted earnings per share of common stock	1.71	0.86	1.41	1.41	1.41	1.41

(1) For the three months ended June 30, 2018, gain on sale includes a \$3 gain associated with the sale of the Company's East Chicago, Indiana site. For the three months ended June 30, 2017, loss on sale includes a \$2 adjustment associated with the sale of the Company's Sulfur business in 2016. For the three months ended March 31, 2018, gain on sale includes a \$42 gain associated with the sale of the Company's Linden, New Jersey site.

(2) Includes costs associated with the Company's debt transactions, as well as accounting, legal, and bankers' transaction costs incurred in connection with the Company's strategic initiatives.

(3) Includes litigation settlements, PFOA drinking water treatment accruals, acquisition-related intangible asset amortization, and other charges.

(4) Includes the removal of certain discrete income tax amounts within the Company's provision for income taxes. For the three months ended June 30, 2018, adjustments made to income taxes includes \$5 in windfall tax benefits on the Company's share-based payments and \$3 in tax benefits resulting from unrealized losses on foreign exchange rates related to toll charges pursuant to U.S. tax reform. For the three months ended June 30, 2017, adjustments made to income taxes includes \$3 in windfall tax benefits on the Company's share-based payments. For the three months ended March 31, 2018, adjustments made to income taxes includes \$5 in windfall tax benefits on the Company's share-based payments.

(5) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

(6) The total provision for income taxes reconciles to the amount reported in the consolidated statements of operations for the three months ended June 30, 2018 and 2017 and for the three months ended March 31, 2018.

* Note: \$ per share columns may not sum due to rounding.

Return on Invested Capital (ROIC) (Unaudited)

(\$ in millions unless otherwise noted)	Twelve Months Ended June 30,	
	2018	2017
Adjusted EBITDA (1)	\$ 1,740	\$ 1,153
Less: Depreciation and amortization (1)	(273)	(287)
Adjusted EBIT	1,467	866
Total debt	3,973	4,070
Total equity	1,025	572
Less: Cash and cash equivalents	(1,217)	(1,529)
Invested capital, net	\$ 3,781	\$ 3,113
Average invested capital (2)	\$ 3,481	\$ 3,158
Return on Invested Capital	42.1%	27.4%

(1) Based on amounts for the trailing 12 months ended June 30, 2018 and 2017. Reconciliations of Adjusted EBITDA to net income (loss) attributable to Chemours are provided on a quarterly basis. See the preceding tables for the reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three months ended June 30, 2018 and 2017.

(2) Average invested capital is based on a five-quarter trailing average of invested capital, net.



Free Cash Flows Reconciliations (Unaudited)

(\$ in millions unless otherwise noted)	Three Months Ended			Six Months Ended	
	June 30,		March 31,	June 30,	
	2018	2017	2018	2018	2017
Cash provided by operating activities	\$ 343	\$ 184	\$ 196	\$ 539	\$ 225
Less: Purchases of property, plant, and equipment	(126)	(69)	(102)	(228)	(138)
Free Cash Flows	\$ 217	\$ 115	\$ 94	\$ 311	\$ 87



2018 Estimated GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS Reconciliations (Unaudited)

(\$ in millions except per share amounts)	(Estimated)	
	Year Ended December 31, 2018	
	Low	High
Net income attributable to Chemours	\$ 985	\$ 1,080
Other adjustments	(45)	(45)
Restructuring, asset-related, and other charges, net	35	25
Provision for income taxes relating to reconciling items (1)	5	5
Adjusted Net Income	<u>980</u>	<u>1,065</u>
Interest expense, net	220	220
Depreciation and amortization	280	280
All remaining provision for income taxes	295	285
Adjusted EBITDA	<u>\$ 1,775</u>	<u>\$ 1,850</u>
Weighted-average number of common shares outstanding - basic (2)	179	179
Dilutive effect of the Company's employee compensation plans (2,3)	6	6
Weighted-average number of common shares outstanding - diluted (2,3)	185	185
Basic earnings per share of common stock	\$ 5.50	\$ 6.03
Diluted earnings per share of common stock (3)	5.32	5.84
Adjusted basic earnings per share of common stock	5.47	5.95
Adjusted diluted earnings per share of common stock (3)	5.30	5.76

(1) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and include both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

(2) The Company's estimates for the weighted-average number of common shares outstanding - basic and diluted reflect results for the year ended December 31, 2017, which are carried forward for the projection period and updated for the estimated impacts of the Company's 2018 share repurchase and other activity on a weighted-average basis.

(3) Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

The Company's estimates reflect its current visibility and expectations of market factors, such as, but not limited to: currency movements, titanium dioxide prices, and end-market demand. Actual results could differ materially from the current estimates due to market factors and unknown or uncertain other factors, such as non-operating pension and other post-retirement employee benefit activity with respect to the Company's foreign pension plans, including settlements or curtailments, cost savings actions that may be taken in the future, the impact of currency movements on the Company's results, including exchange gains and losses, and the related tax effects, or the impact of new accounting pronouncements.



2018 Estimated GAAP Cash Flows Provided by Operating Activities to Free Cash Flows Reconciliations (Unaudited)

(\$ in millions unless otherwise noted)	(Estimated) Year Ended December 31, 2018
Cash provided by operating activities	> \$1,225
Less: Purchases of property, plant, and equipment	(525) - (475)
Free Cash Flows	> \$700

The Company's estimates reflect its current visibility and expectations of market factors, such as, but not limited to: currency movements, titanium dioxide prices, and end-market demand. Actual results could differ materially from the current estimates due to market factors and unknown or uncertain other factors, such as non-operating pension and other post-retirement employee benefit activity with respect to the Company's foreign pension plans, including settlements or curtailments, cost savings actions that may be taken in the future, the impact of currency movements on the Company's results, including exchange gains and losses, and the related tax effects, or the impact of new accounting pronouncements.



The Chemours Company

